Utrecht

• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal … Recruiting
  2024-512302-25-00 5 2025-06-06 Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
• Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or … Recruiting
  2024-514531-18-00 3 2025-05-20 Acute Myeloid Leukemias
• A study to evaluate the benefit of adding durvalumab after chemotherapy, durvalumab and surgery in patients with early-stage, operable, non- … Recruiting
  2023-508773-82-00 5 2025-05-06 Stage IIB-IIIB (N2) resectable non small cell lung cancer
• Setmelanotide in the ROHHAD-syndrome (ROH-SET study) Recruiting
  2024-516753-45-00 4 2025-04-25 ROHHAD syndrome
• Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing morbid curative sur … Recruiting
  2024-516152-17-00 4 2025-04-24 Cutaneous squamous cell carcinoma
• A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido … Recruiting
  2024-515279-37-00 5 2025-04-17 Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
• A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti … Recruiting
  2024-513053-69-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• Transtympanic sodium thiosulfate to prevent cisplatin-related hearing loss, a randomized controlled multicenter phase III trial; The SOUND t … Recruiting
  2023-503313-30-01 5 2025-04-14 Head and Neck squamous cell carcinoma
• StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial Recruiting
  2024-517343-31-00 6 2025-04-11 Ischemic stroke and transient ischemic attack
• A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting
  2024-512633-32-00 4 2025-04-07 Crohn's disease
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L … Recruiting
  2022-501489-24-00 5 2025-03-28 First-line treatment of adult subjects with high-risk large B-cell lym
• Ziftomenib in combination with chemotherapy for children with relapsed/refractory acute leukemia Recruiting
  2023-505262-28-00 3 2025-03-24 Acute Myeloid Leukemia
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Recruiting
  2024-513547-82-00 5 2025-03-11 Transthyretin Amyloidosis
• Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting
  2024-513443-93-00 4 2025-03-10 Recurrent Meningioma without local treatment options (Surgery or Radio
• A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple Myeloma Recruiting
  2024-515316-44-00 3 2025-02-24 Multiple Myeloma
• RECLAIM: an Adaptive Platform Trial for the Evaluation of Treatments for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Recruiting
  2024-511580-28-02 5 2025-02-20 PASC: post-acute sequelae of SARS-CoV-2 infection
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• A Phase 2 Study to Evaluate DNTH103 in Adults with Multifocal Motor Neuropathy (MOMENTUM) Recruiting
  2024-513128-40-00 4 2025-02-06 Multifocal Motor Neuropathy
• CXCR4-directed [68Ga]Ga-PentixaFor PET/CT vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in p … Recruiting
  2024-512628-12-00 10 2025-01-28 Primary aldosteronism
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• Safe Stop Trial Melanoma Recruiting
  2024-516937-10-01 5 2024-12-18 Melanoma

Showing 193–216 of 628 trials